Skip to content
← All ETFs
IBB

iShares Biotechnology ETF

The largest biotechnology ETF tracking the ICE Biotechnology Index. High risk/reward profile with exposure to drug development pipelines. More concentrated and volatile than broad healthcare (XLV). Pairs with XBI for different biotech weighting approaches.

EquityTER 0.44%Dist.US-domiciled
TER
0.44%
AUM
$6B
Holdings
~270
Data Range
— → —

Key Facts

ISIN
US4642875565
Issuer
BlackRock
Benchmark
ICE Biotechnology Index
Total Expense Ratio (TER)
0.44%
Assets Under Management
$6B approx.
Inception Date
2001-02-05
Domicile
US
Legal Structure
Open-End Fund
Dividend Policy
Distributing (pays dividends)
Replication Method
Physical (Full Replication)
UCITS Status
✗ Not UCITS
Fund Currency
USD
Primary Exchange
Nasdaq
Number of Holdings
~270

Top 10 Holdings

Top 10 represent 45.5% of the fund.

1
GILDGilead Sciences
8.20%
2
AMGNAmgen Inc.
8.00%
3
REGNRegeneron Pharma
7.50%
4
VRTXVertex Pharma
7.00%
5
MRNAModerna Inc.
3.50%
6
ILMNIllumina Inc.
2.80%
7
ALNYAlnylam Pharma
2.50%
8
BMRNBioMarin Pharma
2.20%
9
BIIBBiogen Inc.
2.00%
10
SGENSeagen Inc.
1.80%

Equivalent ETFs

These ETFs track the same or very similar underlying index:

Backtest this ETFOfficial Fund Page

Who Is This ETF For?

General portfolio building block for the asset class it covers.

Key Risks to Consider

Market risk: equity values can drop 30-50% in severe bear markets.

Non-UCITS: may have unfavorable tax treatment for non-US investors (US estate tax, withholding tax).

Similar ETFs

Continue Your Analysis

Data & Methodology

Metadata sourced from official issuer documentation. Price data from Yahoo Finance (monthly adjusted close, includes reinvested dividends and splits). AUM figures are approximate and updated quarterly.

Data source: Yahoo Finance (IBB), iShares (metadata)Last verified: 2026-05-06

Related Guides from FinClaro Chile

Related ETFs

UCITS Equivalent

XBI

SPDR S&P Biotech ETF

TER 0.35%$8B AUM

Similar ETFs

SPY

SPDR S&P 500 ETF Trust

TER 0.09%$570B AUM
VOO

Vanguard S&P 500 ETF

TER 0.03%$560B AUM
IVV

iShares Core S&P 500 ETF

TER 0.03%$560B AUM
VTI

Vanguard Total Stock Market ETF

TER 0.03%$435B AUM

Alternative Approaches

QQQ

Invesco QQQ Trust

TER 0.20%$310B AUM
VUG

Vanguard Growth ETF

TER 0.04%$130B AUM
VTV

Vanguard Value ETF

TER 0.04%$130B AUM
IEFA

iShares Core MSCI EAFE ETF

TER 0.07%$125B AUM

💬 Frequently Asked Questions

The largest biotechnology ETF tracking the ICE Biotechnology Index. High risk/reward profile with exposure to drug development pipelines. More concentrated and volatile than broad healthcare (XLV). Pairs with XBI for different biotech weighting approaches.
IBB has a total expense ratio (TER) of 0.44%, which means you pay $44 per year for every $10,000 invested.
Yes, IBB is a distributing ETF that pays dividends to shareholders. The frequency depends on the fund's schedule.
IBB is a US-domiciled ETF (not UCITS). Non-US investors should consider the US estate tax implications (40% on US assets above $60,000) and the 30% dividend withholding tax (reduced by treaty in some countries).
IBB uses full physical replication, meaning it holds all (or nearly all) securities in the ICE Biotechnology Index index directly.
Similar ETFs tracking the same or a very similar index include: XBI. These may differ in domicile, currency, dividend policy, or expense ratio.